Abstract: In 2020, China's biopharmaceutical industry has shown its gushing vitality and accelerated transformation in face of the challenges. In 2021, the further deepening and full implementation of healthcare policy reforms set higher benchmarks of quality and sustainability for the biopharmaceutical industry in the country. Through a series of brainstorming roundtables, Shanghai Center for Innovation Drug Discovery and Development (SCIDDD) proposed its 2021 outlook for China's biopharmaceutical industry, which highlights the importance for biopharmaceutical enterprises to seize innovation opportunities in the new environment of uncertainty.